Cargando…

Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness

Only a subset of cancer patients responds to checkpoint blockade inhibition in the clinic. Strategies to overcome resistance are promising areas of investigation. Targeting glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR) has shown efficacy in preclinical models, but GITR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirschhorn, Daniel, Betof Warner, Allison, Maniyar, Rachana, Chow, Andrew, Mangarin, Levi M.B., Cohen, Adam D., Hamadene, Linda, Rizzuto, Gabrielle A., Budhu, Sadna, Suek, Nathan, Liu, Cailian, Houghton, Alan N., Merghoub, Taha, Wolchok, Jedd D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564916/ https://www.ncbi.nlm.nih.gov/pubmed/34676831 http://dx.doi.org/10.1172/jci.insight.151035

Ejemplares similares

Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment
por: Zappasodi, Roberta, et al.
Publicado: (2014)

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
por: Cohen, Adam D., et al.
Publicado: (2010)

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2013)

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2014)

Induction of tumoricidal function in CD4(+) T cells is associated with concomitant memory and terminally differentiated phenotype
por: Hirschhorn-Cymerman, Daniel, et al.
Publicado: (2012)

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
por: Ricca, Jacob M., et al.
Publicado: (2018)

Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
por: Budhu, Sadna, et al.
Publicado: (2021)

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
por: Campesato, Luis Felipe, et al.
Publicado: (2020)

Self-antigen–specific CD8(+) T cell precursor frequency determines the quality of the antitumor immune response
por: Rizzuto, Gabrielle A., et al.
Publicado: (2009)

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
por: Ghosh, Arnab, et al.
Publicado: (2022)

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
por: Hirschhorn-Cymerman, Daniel, et al.
Publicado: (2009)

The future of cancer immunotherapy: microenvironment-targeting combinations
por: Murciano-Goroff, Yonina R., et al.
Publicado: (2020)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer
por: Gupta, Aditi, et al.
Publicado: (2021)

Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism
por: He, Changhao, et al.
Publicado: (2022)

Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014)

Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
por: Chapman, Paul B., et al.
Publicado: (2023)

Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions
por: Schad, Sara E., et al.
Publicado: (2022)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
por: Davar, Diwakar, et al.
Publicado: (2022)

Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity
por: Avogadri, Francesca, et al.
Publicado: (2010)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope
por: Schaer, David A., et al.
Publicado: (2011)

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
por: Schaer, David A, et al.
Publicado: (2014)

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
por: Holmgaard, Rikke B., et al.
Publicado: (2016)

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
por: Oseledchyk, Anton, et al.
Publicado: (2018)

Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids
por: Tokunaga, Akihiro, et al.
Publicado: (2019)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
por: Holmgaard, Rikke B, et al.
Publicado: (2014)

CD8(+) T Cells: GITR Matters
por: Ronchetti, Simona, et al.
Publicado: (2012)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Mathematical modeling suggests cytotoxic T lymphocytes control growth of B16 tumor cells in collagin-fibrin gels by cytolytic and non-lytic mechanisms
por: Majumder, Barun, et al.
Publicado: (2023)

Cytotoxic T Lymphocytes Control Growth of B16 Tumor Cells in Collagen–Fibrin Gels by Cytolytic and Non-Lytic Mechanisms
por: Majumder, Barun, et al.
Publicado: (2023)

An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
por: Chan, Sarah, et al.
Publicado: (2022)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
por: Yang, Ning, et al.
Publicado: (2022)

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors
por: Zappasodi, Roberta, et al.
Publicado: (2021)

The Role of GITR/GITRL Interaction in Autoimmune Diseases
por: Tian, Jie, et al.
Publicado: (2020)

Targeting GITR in cancer immunotherapy – there is no perfect knowledge
por: Davar, Diwakar, et al.
Publicado: (2023)

Oligoclonality of human intestinal intraepithelial T cells
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_oprudj6ubhn8ufikgokilhavs1